P-selectin and sST2 as prognostic biomarkers of cardiovascular events in patients with multiple myeloma following anticancer therapy and severe COVID-19
This study investigates the prognostic value of sST2 and P-selectin as biomarkers for cardiovascular risk in patients with multiple myeloma (MM) who are in remission following anticancer therapy and have experienced severe COVID-19. The topic is of increasing clinical relevance due to the growing in...
Saved in:
| Main Authors: | B. B. Samura, M. O. Panasenko, T. O. Samura, I. V. Chorna |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Zaporizhzhia State Medical and Pharmaceutical University
2025-07-01
|
| Series: | Aktualʹnì Pitannâ Farmacevtičnoï ì Medičnoï Nauki ta Praktiki |
| Subjects: | |
| Online Access: | https://pharmed.zsmu.edu.ua/article/view/329039/323378 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic value of P-selectin and sST2 in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-11-01) -
Value of P-selectin in the prognosis of cardiovascular events in patients with multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-08-01) -
Circulating sST2 and prognosis of cardiovascular events in remission of multiple myeloma
by: M. O. Panasenko, et al.
Published: (2022-10-01) -
Cardiovascular events after polychemotherapy of multiple myeloma: modern ways to diagnostics
by: B. B. Samura, et al.
Published: (2020-03-01) -
Cariohemodynamics in patients with multiple myeloma depending on renal function
by: B. B. Samura, et al.
Published: (2019-12-01)